New therapeutic agents in the management of HIV: an overview of darunavir for clinicians

Article

<< Previous

Next >>

Contents Vol 5(3)

doi:10.1071/SH08005

New therapeutic agents in the management of HIV: an overview of darunavir for clinicians

Jessica Rotty ^A ^C, Jennifer Hoy ^A ^B

^A Infectious Diseases Unit, Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia.
^B Department of Medicine, Monash University, Melbourne, Vic. 3168, Australia.
^C Corresponding author. Email: j.rotty@alfred.org.au





	PDF (115 KB) $25



	Export Citation

Print

Sexual Health 5(3) 235–241 http://dx.doi.org/10.1071/SH08005
Submitted: 15 January 2008 Accepted: 16 April 2008 Published online: 6 August 2008

Abstract

This overview will provide the reader with summarised information about darunavir, a new protease inhibitor licenced for the treatment of drug resistant HIV-infection. Darunavir is a promising new drug with good clinical efficacy data and safety profile. In this overview clinicians will be updated on clinical efficacy data, side-effects, resistance profile and drug interactions. The overview should give clinicians a sound understanding of when and how to use this new protease inhibitor in the treatment of HIV-infection.

Keywords: drug resistance, HAART, Prezista, protease inhibitor.